Welcome to chemicalbook!
Chinese English Japanese Germany Korea
010-86108875
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

ChemicalBook CAS DataBase List Relebactam
1174018-99-5

Relebactam synthesis

12synthesis methods
Relebactam, also known as MK-7655, a potent and selective β-lactamase inhibitor. At a concentration of 4 mg/L, MK-7655 reduced imipenem MICs for Enterobacteriaceae with KPC carbapenemases from 16-64 mg/L to 0.12-1 mg/L. MK-7655 potentiated imipenem against Enterobacteriaceae with KPC carbapenemases or combinations of β-lactamase and impermeability, but not those with metallo-carbapenemases. It augmented the activity of imipenem against P. aeruginosa in general and OprD mutants in particular. Synthetic Description Reference: Mangion, Ian K.; Ruck, Rebecca T.; Rivera, Nelo; Huffman, Mark A.; Shevlin, Michael. A concise synthesis of a β-lactamase inhibitor. Organic Letters. Volume 13. Issue 20. Pages 5480-5483. Journal; Online Computer File. (2011). Synthetic Description Reference: Liu, Zhijian; Yasuda, Nobuyoshi; Simeone, Michael; Reamer, Robert A. N-Boc Deprotection and Isolation Method for Water-Soluble Zwitterionic Compounds. Journal of Organic Chemistry. Volume 79. Issue 23. Pages 11792-11796. Journal; Online Computer File. (2014). Synthetic Description Reference: Wankhede, Karuna Suresh; Surwase, Mahesh Manikrao; Bhawsar, Satish; Deshpande, Prasad Keshav; Yeole, Ravindra Dattatraya; Patel, Mahesh Vithalbhai. A process for preparation of (2S,5R)- sulfuric acid mono-{[(4-aminopiperidin-4-yl) carbonyl]-7-oxo-1,6-diazabicyclo[3.2.1]-oct-6-yl}ester. Assignee Wockhardt Limited, India. IN 296654. (2018 Synthetic Description Reference: Gordon, Eric M.; Freund, John; Gallop, Mark A.; Duncton, Matthew Alexander James. Beta-lactamase inhibitors and uses thereof. Assignee Arixa Pharmaceuticals, Inc., USA. US 10085999. (2018). Synthetic Description Reference: Miller, Steven P.; Limanto, John; Zhong, Yong-Li; Yasuda, Nobuyoshi; Liu, Zhijian. Preparation of tert-butyl 4-((1R,2S,5R)-6- (benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamido)piperidine-1-carboxylate. Assignee Merck Sharp & Dohme Corp., USA. WO 2014200786. (2014).
Synthetic Routes
  • ROUTE 1
  • 202112071381048902.jpg

    Reference: Mangion, Ian K.; Ruck, Rebecca T.; Rivera, Nelo; Huffman, Mark A.; Shevlin, Michael. A concise synthesis of a β-lactamase inhibitor. Organic Letters. Volume 13. Issue 20. Pages 5480-5483. Journal; Online Computer File. (2011).

  • ROUTE 2
  • 202112077503315526.jpg

    Reference: Liu, Zhijian; Yasuda, Nobuyoshi; Simeone, Michael; Reamer, Robert A. N-Boc Deprotection and Isolation Method for Water-Soluble Zwitterionic Compounds. Journal of Organic Chemistry. Volume 79. Issue 23. Pages 11792-11796. Journal; Online Computer File. (2014).

  • ROUTE 3
  • 202112076360676885.jpg

    Reference: Wankhede, Karuna Suresh; Surwase, Mahesh Manikrao; Bhawsar, Satish; Deshpande, Prasad Keshav; Yeole, Ravindra Dattatraya; Patel, Mahesh Vithalbhai. A process for preparation of (2S,5R)- sulfuric acid mono-{[(4-aminopiperidin-4-yl) carbonyl]-7-oxo-1,6-diazabicyclo[3.2.1]-oct-6-yl}ester. Assignee Wockhardt Limited, India. IN 296654. (2018

  • ROUTE 4
  • 202112073723657817.jpg

    Reference: Gordon, Eric M.; Freund, John; Gallop, Mark A.; Duncton, Matthew Alexander James. Beta-lactamase inhibitors and uses thereof. Assignee Arixa Pharmaceuticals, Inc., USA. US 10085999. (2018).

  • ROUTE 5
  • 202112075606641404.jpg

    Reference: Miller, Steven P.; Limanto, John; Zhong, Yong-Li; Yasuda, Nobuyoshi; Liu, Zhijian. Preparation of tert-butyl 4-((1R,2S,5R)-6- (benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamido)piperidine-1-carboxylate. Assignee Merck Sharp & Dohme Corp., USA. WO 2014200786. (2014).

202112071381048902.jpg

Reference: Mangion, Ian K.; Ruck, Rebecca T.; Rivera, Nelo; Huffman, Mark A.; Shevlin, Michael. A concise synthesis of a β-lactamase inhibitor. Organic Letters. Volume 13. Issue 20. Pages 5480-5483. Journal; Online Computer File. (2011).

N,N,N-tributylbutan-1-aminium [({(2S,5R)-7-oxo-2-[(piperidin-4-ylamino)carbonyl]-1,6-diazabicyclo[3.2.1]oct-6-yl}oxy)sulfonyl]oxidanide

1174020-24-6
5 suppliers
inquiry

-

Yield:1174018-99-5 83.8%

Reaction Conditions:

Stage #1: tetrabutyl ammonium salt (25,5R)-4-tert-butyl{(6-sulfooxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-ylcarbonyl)amino}piperidine-1-carboxylatewith tetrafluoroboric acid in 2,2,2-trifluoroethanol at 18 - 22; for 12.1833 h;
Stage #2: with sodium hydrogencarbonate in dichloromethane;2,2,2-trifluoroethanol;water at 18.5; pH=4.5;Product distribution / selectivity;

Steps:

1C.12

The solution of Bu4N+OSθ3 salt in TFE (34 L) was used as received from the prior step with an assumed yield of 100%. The reaction mixture was cooled in an ice bath, and HBF4-Et2θ (1.57 L) was added via addition funnel over 11 minutes between 180C and 220C.The resulting white slurry was allowed to stir overnight (12 hours). TFE (-15 L) was removed by vacuum distillation. DCM (15 L) was then added. To a 100-L extractor was charged pyrogen-free water (35 L) and NaHCθ3 (274 g), and the solution was cooled to 13°C. The reaction mixture was transferred by vacuum into the extractor with temperature of 11-130C. The reaction flask was rinsed with additional DCM (5 L) and the suspension also transferred to the extractor. The reaction mixture was warmed to 18.5 0C and de-pyrogenated water (12 L) was added to solubilize all the solids. The final pH was 4.5. The organic layer was separated, and the aqueous layer was washed with DCM (2 x 16 L). Assay of the aqueous layer showed 2.38 kg (83.8 %)The aqueous layer was charged to a clean flask. The solution was concentrated by vacuum distillation followed by azeotropic distillation with IPA. At this time, lH NMR analysis of the IPA:H2θ ratio indicated the presence of 13.4 L of water and 24.6 L of IPA. IPA (22 L) was added. The white crystalline solid was filtered and washed with 7:1 IPA:de-pyrogenated water (16 L) and dried under vacuum and nitrogen at room temperature to afford the title product in the form of a crystalline channel hydrate, 1.5 wt% water. (Yield = 1.715 kg, 57.4% over Steps 11 and 12). 1H NMR (400 MHz5 DMSOd6 ): 8.3 (br s, 2H)5 8.21 (d, J- 7.8 Hz, IH), 4.01(s, IH), 3.97-3.85 (m, IH), 3.75 (d, J= 6.5 Hz, IH) 3.28(dd, J= 12.9, 2.5 Hz, 2H) 3.05-2.93(m, 4H), 2.08-1.97(m, IH), 1.95-1.79(m, 3H), 1.75-1.59(m, 4H)

References:

WO2009/91856,2009,A2 Location in patent:Page/Page column 71-72

1510832-19-5 Synthesis
tert-butyl 4-((2S,5R)-5-(benzyloxyamino)piperidine-2-carboxamido)piperidine-1-carboxylate 4-methylbenzenesulfonate

1510832-19-5
25 suppliers
inquiry

Relebactam Related Search: